Healthcare / Pharmaceutical RetailersTaipei Exchange
$53.60
-0.10 (-0.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $572.1M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
14.8x
↓EV/EBITDA
5.3x
↓ROE
10.0%
↑Gross Margin
32.5%
↓Debt/Equity
2.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.5%
FCF CAGR
-8.1%
FCF margin
7.8%
FCF / Net income
4.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.01B · net income $155.5M · FCF $624.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.01B | $8.01B | $7.73B | $7.45B | $7.22B |
| Net Income | $155.5M | $155.5M | $69.8M | $46.8M | $170.9M |
| EBITDA | $1.03B | $1.03B | $924.3M | $873.3M | $942.0M |
| EPS | — | — | 1.65 | 1.12 | 4.09 |
| Gross Margin | 32.5% | 32.5% | 30.8% | 30.5% | 30.5% |
| Operating Margin | 2.6% | 2.6% | 1.6% | 1.4% | 3.1% |
| Net Margin | 1.9% | 1.9% | 0.9% | 0.6% | 2.4% |
| Balance Sheet | |||||
| Debt/Equity | 2.30 | 2.30 | 2.50 | 2.68 | 2.89 |
| Current Ratio | 0.83 | 0.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $624.4M | $624.4M | $404.8M | $572.1M | $805.4M |
| Returns | |||||
| ROE | 10.0% | 10.0% | 4.8% | 3.2% | 12.5% |
| Valuation | |||||
| P/E | 14.77 | 14.77 | 39.82 | 77.68 | 17.02 |
| EV/EBITDA | 5.30 | 5.30 | 6.38 | 7.58 | 6.25 |
| P/B | 1.45 | 1.45 | 1.91 | 2.55 | 2.16 |
| Growth & Yield | |||||
| Revenue Growth | 3.6% | 3.6% | 3.9% | 3.1% | — |
| EPS Growth | — | — | 47.3% | -72.6% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.5%
Start / end P/E
n/dx → n/dx
EPS bridge
1.65 → n/d
Residual
-19.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.